Elite in Fukuyama Type Muscular Dystrophy

Dr. Katherine D. Mathews

Neurology | Pediatrics | Pediatric Neurology
State University Of Iowa
200 Hawkins Dr, 
Iowa City, IA 
Accepting New Patients
Elite in Fukuyama Type Muscular Dystrophy
State University Of Iowa
200 Hawkins Dr, 
Iowa City, IA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Katherine Mathews is a Neurologist and a Pediatrics provider in Iowa City, Iowa. Dr. Mathews and is rated as an Elite provider by MediFind in the treatment of Fukuyama Type Muscular Dystrophy. Her top areas of expertise are Limb-Girdle Muscular Dystrophy Type 2I, Limb-Girdle Muscular Dystrophy, Duchenne Muscular Dystrophy, and Friedreich Ataxia. Dr. Mathews is currently accepting new patients.

Her clinical research consists of co-authoring 120 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Fukuyama Type Muscular Dystrophy.

Specialties
Neurology
Pediatrics
Pediatric Neurology
Licenses
Neurology with Special Qualifications in Neurology in IA
Hospital Affiliations
University Of Iowa Hospital & Clinics
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Centene

Accepted plan types not found. Please verify directly with the provider.

Cigna
  • EPO
  • HMO
  • PPO
Clear Spring Health

Accepted plan types not found. Please verify directly with the provider.

Elixir

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independence
  • EPO
  • HMO
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid

Accepted plan types not found. Please verify directly with the provider.

Medical Associates

Accepted plan types not found. Please verify directly with the provider.

Medicare

Accepted plan types not found. Please verify directly with the provider.

Molina

Accepted plan types not found. Please verify directly with the provider.

Northern Plains Alliance

Accepted plan types not found. Please verify directly with the provider.

Oscar
  • EPO
  • HMO
  • PPO
Sanford

Accepted plan types not found. Please verify directly with the provider.

Sanford Health
  • HMO
  • PPO
Silverscript

Accepted plan types not found. Please verify directly with the provider.

WellCare Health Plans

Accepted plan types not found. Please verify directly with the provider.

Wellmark
  • HMO
  • POS
View 18 Less Insurance Carriers -

Locations

STATE UNIVERSITY OF IOWA
200 Hawkins Dr, Iowa City, IA 52242

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, Then Dose Expansion, in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, Then Dose Expansion, in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
Enrollment Status: Terminated
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: SRP-5051 Exon 51-Skipping Treatment
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 24, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2024
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Genetic
Study Phase: Phase 3
Clinical Outcome Measures in Friedreich's Ataxia
Clinical Outcome Measures in Friedreich's Ataxia
Enrollment Status: Active_not_recruiting
Publish Date: October 04, 2024
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)
Enrollment Status: Active_not_recruiting
Publish Date: June 07, 2024
Intervention Type: Drug
Study Drug: Omaveloxolone
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Enrollment Status: Enrolling_by_invitation
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Drug
Study Drug: Tideglusib
Study Phase: Phase 2/Phase 3
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
Enrollment Status: Terminated
Publish Date: June 27, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 15 Less Clinical Trials

120 Total Publications

Clinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study.
Clinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study.
Journal: Annals of clinical and translational neurology
Published: January 08, 2025
Similar Doctors
Advanced in Fukuyama Type Muscular Dystrophy
Dr. Andrea J. Swenson
Neurology
Advanced in Fukuyama Type Muscular Dystrophy
Dr. Andrea J. Swenson
Neurology

State University Of Iowa

200 Hawkins Dr, 
Iowa City, IA 
 (0.1 mi)
319-356-1616
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrea Swenson is a Neurologist in Iowa City, Iowa. Dr. Swenson and is rated as a Distinguished provider by MediFind in the treatment of Fukuyama Type Muscular Dystrophy. Her top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Myasthenia Gravis, Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), and Rhizotomy. Dr. Swenson is currently accepting new patients.

Advanced in Fukuyama Type Muscular Dystrophy
Dr. Ludwig Gutmann
Neurology
Advanced in Fukuyama Type Muscular Dystrophy
Dr. Ludwig Gutmann
Neurology
200 Hawkins Dr, Dept Of Neurology, 
Iowa City, IA 
 (0.1 mi)
319-356-3096
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ludwig Gutmann is a Neurologist in Iowa City, Iowa. Dr. Gutmann and is rated as a Distinguished provider by MediFind in the treatment of Fukuyama Type Muscular Dystrophy. His top areas of expertise are Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal Muscular Atrophy Type 3, and Spinal and Bulbar Muscular Atrophy. Dr. Gutmann is currently accepting new patients.

Experienced in Fukuyama Type Muscular Dystrophy
Dr. Christopher S. Nance
Neurology
Experienced in Fukuyama Type Muscular Dystrophy
Dr. Christopher S. Nance
Neurology

State University Of Iowa

200 Hawkins Dr, 
Iowa City, IA 
 (0.1 mi)
319-356-1616
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christopher Nance is a Neurologist in Iowa City, Iowa. Dr. Nance and is rated as a Distinguished provider by MediFind in the treatment of Fukuyama Type Muscular Dystrophy. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal Muscular Atrophy (SMA), Spinal and Bulbar Muscular Atrophy, Transmyocardial Revascularization, and Stent Placement. Dr. Nance is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mathews's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 11 Distinguished Conditions
View All 29 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile